B-cell precursor acute lymphoblastic leukemia (ALL) in remission when only a small number of cancer cells remain in the body (minimal residual disease)...read more
B-cell precursor acute lymphoblastic leukemia (ALL) in remission when only a small number of cancer cells remain in the body (minimal residual disease)...read more
While discussing your ALL treatment, your doctor may have talked to you about BLINCYTO®, an immunotherapy.1
BLINCYTO® is an immunotherapy that helps fight ALL. It is different from chemotherapy. BLINCYTO® works with your immune system to find and destroy cancer cells.1,2
In a study of 405 adults with relapsed or refractory Ph(–) BCP-ALL, BLINCYTO® was tested against commonly prescribed chemotherapy. It showed that common side effects of chemotherapy, including nausea and vomiting, showed up less often in adults treated with BLINCYTO®.1,3
Now let’s see how well BLINCYTO® worked in the study.
In the study, 271 people were treated with BLINCYTO® and 134 people were treated with chemotherapy.1
What’s more, when treated after first relapse, people on BLINCYTO® had a median survival of 11.1 months vs those on chemotherapy who had a median survival of 5.5 months.4
*Median overall survival is defined as the length of time from the start of treatment to when half of the patients in a treatment group are still alive.2
BLINCYTO® may cause serious side effects that can be severe, life-threatening, or lead to death. These include cytokine release syndrome (CRS), infusion reactions, and neurologic problems.
People with Down Syndrome over the age of 10 years may have a higher risk of seizures with BLINCYTO® treatment.
These are not all the possible side effects of BLINCYTO®.
Call your health care provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Tell your health care provider right away if you develop an infection or fever, or if you have any side effects that bother you or do not go away.
What is the most important information I should know about BLINCYTO®?
Who should not receive BLINCYTO®?
Before receiving BLINCYTO®, tell your health care provider about all of your medical conditions, including if you or your child:
What should I avoid while receiving BLINCYTO®?
BLINCYTO® may cause serious side effects, including:
The most common side effects
These are not all the possible side effects of BLINCYTO®.
Call your health care provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please read the accompanying Medication Guide before you or your child receives BLINCYTO® and before each BLINCYTO® infusion and discuss it with your doctor.
Please see BLINCYTO® full Prescribing Information, including BOXED WARNINGS and Medication Guide.
What is the most important information I should know about BLINCYTO®?
References: 1. BLINCYTO® (blinatumomab) prescribing information, Amgen. 2. National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed May 3, 2024. 3. Data on file, Amgen; 2016. 4. Dombret H, Topp MS, Schuh AC, et al. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60:2214-2222. 5. BLINCYTO® (blinatumomab) medication guide, Amgen.